INDIVIOR PHARMACEUTICALS INC (INDV)
Health Care · specialty pharmaceuticals · NASDAQ
A pharmaceutical company specialized in innovative treatments for substance use and mental health disorders.
What INDIVIOR PHARMACEUTICALS INC does
Indivior Pharmaceuticals is a pharmaceutical company focused on developing and commercializing treatments for substance use disorders and mental health conditions. Its business is built on a portfolio of therapies for opioid use disorder and other related conditions. The company is actively pursuing growth through internal development and potential strategic acquisitions, such as its proposed merger with Supernus Pharmaceuticals.
Themes: substance use disorder treatment, mental health, specialty pharmaceuticals
Fundamentals
- Price$36.87 as of 2026-08-21 close
- Market cap$4.4B as of 2026-08-21
- 1-year return+53.3% 2025-08-21 close $24.05 → 2026-08-21 close $36.87
- P/E12.77 as of 2026-08-24
- Net margin+26.6% as of 2026-08-24
- Gross margin+82.0% as of 2026-08-24
- ROE+159.1% as of 2026-08-24
- Debt / equity27.90 as of 2026-08-24
- Revenue growth (YoY)+13.6% as of 2026-08-24
- Revenue CAGR (3y)+11.2% SEC XBRL
- Beta0.58 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How INDV compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
INDV is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
48.5 #896 of 1,704 scored · #157 of 240 in Health Care
Volume and participation 84th: it gapped 6.1% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; setup 48th: day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 78% of it); weakest is trend 37th: it is trading 6.8% below its 50-day average, the short-term trend line.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How INDIVIOR PHARMACEUTICALS INC looks technically
INDIVIOR PHARMACEUTICALS INC (INDV) is trading 4.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 303 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day low about 14 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 4.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +4.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $39.56 | $39.56 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $35.23 | $35.23 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 38.56. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 303 trading days ago — a "golden cross", a bullish long-term signal | 303 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 18.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30) | 37.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($35.76 to $40.00) — its "stochastic" reading is 26 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 26.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $42.81 | $42.81 |
|---|---|---|
| From the 52-week high | it is 13.9% below its 52-week high (its highest price of the past year) | -13.9% |
| Above the 52-week low | it is 65.9% above its 52-week low (its lowest price of the past year) | +65.9% |
| Below the 52-week high | it is 13.9% below its highest point of the past year | 13.9% |
| Since a 20-day breakout | it made a new 20-day low about 14 trading days ago | 14 sessions |
| Since a 55-day breakout | it made a new 55-day high about 40 trading days ago | 40 sessions |
| All-time high | its highest closing price on record is $42.81 (set on 2026-06-26) | $42.81 |
| Given back of the 52-week move | over the past year its closes ranged ($22.51 to $41.83), and it has given back roughly a quarter of its rise from last year’s low — 26% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $29.27 to $29.89. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 25.7% |
| From the all-time high | it is 13.9% below its all-time high | -13.9% |
| Nearest price level | it is trading 2.4% below a resistance level at $37.77 — a price it turned at three times since 2025-12-08, most recently on 2026-06-22. Since 2024-08-21 it has 12 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.4% |
| All-time low | its lowest closing price on record is $1.75 (set on 2019-04-10) | $1.75 |
| Above the all-time low | it is 2006.9% above its all-time low | +2,007% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 78% of it) | 22nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.45 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.45 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $36.60 and $41.05 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $36.60 – $38.83 – $41.05 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges above its 200-day average price (4.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.16× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.3% |
|---|---|---|
| Open gap | it gapped 6.1% above the previous close 51 sessions ago and has not traded back through the level it left behind at 35.43 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.1% |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -6.49% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 11.2 percentage points (the stock lost 8.9% while the market gained 2.3%) | -11.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.7 percentage points (the stock lost 1.6% while the market gained 3.1%) | -4.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 2.3 percentage points (the stock gained 8.8% while the market gained 11.1%) | -2.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 32.8 percentage points (the stock gained 53.3% while the market gained 20.5%) | +32.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.0% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.2% of the share price. | -2.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $35.48 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +3.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is under water. That average is $38.04 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | -3.1% |
Price levels it has turned at before
INDV last closed at $36.87 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $37.77 | Resistance | 2.4% above the last close | turned there three times · 2025-12-08 to 2026-06-22 |
| $35.46 | Support | 3.8% below the last close | turned there six times · 2025-12-16 to 2026-08-04 |
| $38.57 | Resistance | 4.6% above the last close | turned there twice · 2026-05-26 to 2026-07-21 |
| $32.41 | Support | 12.1% below the last close | turned there twice · 2025-11-06 to 2026-06-02 |
| $41.75 | Resistance | 13.2% above the last close | turned there twice · 2026-07-16 to 2026-07-29 |
| $29.39 | Support | 20.3% below the last close | turned there twice · 2025-11-14 to 2026-03-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $38.56.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $37.15 and $38.56 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $35.76.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud · Elliott wave 4 pullbacks | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$49.00 range $43.00 – $53.00; median $50.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for INDV
- Consensus EPS estimate$1.12 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a concentrated portfolio of products for substance use disorders and associated revenue volatility.","Risks related to the successful integration and realization of anticipated synergies from the proposed merger with Supernus.","Potential for increased competition, evolving regulatory environments, and ongoing litigation risks."]
What changed in the latest 10-Q
AI-assisted comparison of INDV's 10-Q filed 2026-04-30 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Added statement: 'As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, Indivior has revolutionized the science of addiction medicine...' in newer filing (2026-04-30)
- Added Recent Developments section detailing $14 million costs associated with Phase II - Accelerate of the Indivior Action Agenda in newer filing (2026-04-30)
- Added announcement of $400 million share repurchase program with $125 million repurchased in Q1 2026 in newer filing (2026-04-30)
- Added information about $500 million convertible senior notes offering due in 2031 and repayment of $333 million term loan in newer filing (2026-04-30)
- Added Research & Development Pipeline Updates section with details on INDV-6001 (Buprenorphine Caproate) license amendment with Alar Pharmaceuticals in newer filing (2026-04-30)
- Added information on INDV-2000 (Rocavorexant) Phase 2 study failure and business development pursuit in newer filing (2026-04-30)
- Added detailed financial comparison table for three months ended March 31, 2026 vs 2025 in newer filing (2026-04-30)
- Added information on SUBLOCADE dispense unit volume growth of 20% in newer filing (2026-04-30)
- Added accrued rebates table for March 31, 2026 vs March 31, 2025 in newer filing (2026-04-30)
- Removed:
- Removed reference to Form 10-K for year ended December 31, 2024 (replaced with December 31, 2025 in newer filing)
- Removed Note 14 reference regarding 'Revision of Previously Issued Financial Statements' accrual overstatement correction
- Removed mention of nalmefene nasal spray for emergency opioid overdose reversal from company's operating focus (removed in newer filing)
- Removed discussion of OPVEE (opioid overdose reversal product) sales and marketing discontinuation decision from 2025
- Removed discussion of Rest of World market optimization plan announced in October 2025 to exit several non-U.S. markets
- Removed mention of cancellation of London Stock Exchange listing and exclusive Nasdaq trading (from July 2025)
- Removed OPVEE revenue line items from financial tables (product discontinued)
- Removed references to IQVIA as data source (replaced with Symphony Health in newer filing)
- Removed nine-month period comparisons (older filing included three and nine month data; newer filing shows only three-month data)
- Reworded:
- Changed company mission statement from 'working to help change patients' lives by developing medicines to treat OUD' and 'vision is that all patients will have access to evidence-based treatment' to emphasis on 'leader in long-acting injectable treatments' and 'revolutionized the science of addiction medicine' in newer filing
- Added descriptive language 'Building on this heritage, Indivior is ushering in a new era, renewing our commitment to individuals living with OUD' in newer filing (2026-04-30)
- Changed SUBLOCADE percentage of net revenue from 70% (Sept 2025) and 69% (nine months Sept 2025) to 73% (Q1 2026) and 66% (Q1 2025) comparisons in newer filing
- Changed Other buprenorphine-based sublingual products percentage from 26% and 28% to 25% and 32% respectively in newer filing
- Changed data source attribution from IQVIA to Symphony Health for SUBOXONE Film BMAT average share data in newer filing (2026-04-30)
- Changed description of 'Phase 1 of the Indivior Action Agenda — Generate Momentum' (from October 2025 filing) to 'Phase II - Accelerate' in newer filing (2026-04-30)
- Notes:
- The two filings compare different periods: newer filing covers Q1 2026 (three months ended March 31, 2026) while older filing covers Q3 2025 (three months ended September 30, 2025), limiting direct operational comparisons
- Older filing included nine-month comparisons while newer filing shows only three-month period data, affecting completeness of comparison
- Text in both filings appears truncated at the end of the accrued rebates section, potentially affecting completeness of MD&A section comparison
Risk Factors
- Added:
- Forward-looking statements now include 'expected future capital expenditures' and 'potential future share repurchases' (newer filing, 2026-04-30)
- Forward-looking statements now reference 'Annual Report on Form 10-K filed February 26, 2026' (newer filing, 2026-04-30)
- Financial statements show 'Loss on debt extinguishment' of $18 million in Q1 2026 (newer filing, 2026-04-30)
- Balance sheet shows 'Long-term debt, less current portion' increased to $486 million as of March 31, 2026 vs. $290 million as of December 31, 2025 (newer filing, 2026-04-30)
- Company name changed from 'Indivior PLC' to 'Indivior Pharmaceuticals, Inc.' in financial statement headers (newer filing, 2026-04-30)
- Common stock par value changed from '$0.50 per share' to '$0.001 per share' (newer filing, 2026-04-30)
- Stock canceled and exchanged as part of U.S. Domestication appears in stockholders' deficit statement for Q1 2026 (newer filing, 2026-04-30)
- Removed:
- Forward-looking statements no longer include 'Company's financial guidance including revenue, gross margin and adjusted EBITDA for 2025 and its medium- and long-term growth outlook' (older filing, 2025-10-30)
- Removed references to 'Annual Report on Form 10-K filed March 3, 2025' and 'Quarterly Reports on Form 10-Q filed May 1, 2025 and July 31, 2025' (older filing, 2025-10-30)
- Removed references to 'Acquired in-process research and development' line item from operations (older filing, 2025-10-30)
- Removed 'Litigation settlement' as separate operating expense line item (older filing, 2025-10-30)
- Removed 'Shareholders' deficit' terminology; replaced with 'Stockholders' deficit' (older filing, 2025-10-30)
- Removed 'Short-term investments' line item from balance sheet (older filing, 2025-10-30)
- Reworded:
- Forward-looking statements section changed from referencing 'potential future investment opportunities' to 'potential investment or acquisition opportunities' (newer filing, 2026-04-30)
- Index header changed from 'Item 1. Unaudited Financial Statements' to 'Item 1. Unaudited Condensed Financial Statements' (newer filing, 2026-04-30)
- Statement of cash flows header changed from 'Statements of Cash Flow' to 'Statements of Cash Flows' (newer filing, 2026-04-30)
- Company name changed from 'Indivior PLC' to 'Indivior Pharmaceuticals, Inc.' throughout financial statements (newer filing, 2026-04-30)
- 'Other comprehensive income' changed from reporting in both three-month and nine-month periods to only reporting three-month period (newer filing, 2026-04-30)
- Balance sheet terminology changed from 'Shareholders' deficit' to 'Stockholders' deficit' (newer filing, 2026-04-30)
- Notes:
- Newer filing covers Q1 2026 (three months ended March 31, 2026); older filing covers Q3 2025 (three months and nine months ended September 30, 2025), making direct period-to-period financial comparison limited
- Newer filing shows U.S. Domestication transaction affecting par value and share structure, indicating significant corporate restructuring
- Cash flow statement in newer filing is truncated and incomplete in the source material provided
- Older filing contained comparative 2024 data; newer filing only presents 2025-2026 data, limiting historical comparison visibility
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 3 open-market sales by insiders in the last 90 days.
- Last 30 days1 buy ($54420) · 0 sells — 1 buying insider
- Last 90 days1 buy ($54420) · 3 sells ($3M) — 1 buying, 2 selling insiders
- Last 180 days1 buy ($54420) · 3 sells ($3M) — 1 buying, 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about INDV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding INDV as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 27,716,112
- Reported value $844,787,101
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
INDV had 10,877,755 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
INDV had 9.22% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.13 days to cover at the same settlement.
- Reported short interest (shares) 10,877,755
- Short interest (% of shares outstanding) 9.22%
- Prior settlement (shares) 11,277,025
- Reported change -3.54%
- Days to cover (reported) 7.13
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alkermes (ALKS)
- BioDelivery Sciences International
- Orexo AB
- Titan Pharmaceuticals
- Supernus Pharmaceuticals (SUPN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare INDV vs…
INDV ranks in…
Frequently asked questions
What does INDIVIOR PHARMACEUTICALS INC (INDV) do?
Indivior Pharmaceuticals is a pharmaceutical company focused on developing and commercializing treatments for substance use disorders and mental health conditions. Its business is built on a portfolio of therapies for opioid use disorder and other related conditions. The company is actively pursuing growth through internal development and potential strategic acquisitions, such as its proposed merger with Supernus Pharmaceuticals.
What sector is INDIVIOR PHARMACEUTICALS INC (INDV) in?
INDIVIOR PHARMACEUTICALS INC (INDV) is classified in the Health Care sector. Its industry is specialty pharmaceuticals. It trades on NASDAQ.
Who are INDIVIOR PHARMACEUTICALS INC's (INDV) competitors?
Notable peers of INDIVIOR PHARMACEUTICALS INC (INDV) include Alkermes, BioDelivery Sciences International, Orexo AB, Titan Pharmaceuticals and Supernus Pharmaceuticals. This peer set is informational only — not financial advice.
Is INDIVIOR PHARMACEUTICALS INC (INDV) overbought or oversold right now?
INDIVIOR PHARMACEUTICALS INC (INDV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 37, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INDV come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.